Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - Glycine transporter type 1 and its inhibitors (Review)

Acta Physiologica Hungarica

Volumn 99, Issue 1, 2012, Pages 1-17

  Harsing, L G ^a   Zsilla, G ^b   Matyus, P ^a   Nagy, K M ^c   Marko, B ^c   Gyarmati, Zs ^a   Timar, J ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

glycine transporter inhibitors; glycine transporters; pyridazinone based glycine transporter inhibitors; sarcosine containing glycine transporter inhibitors

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; 4 AMINOBUTYRIC ACID; ALANINE; BETA ALANINE; CARRIER PROTEIN; DEXTRO ALANINE; DIMETHYLGLYCINE; GLYCINE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; INHIBITOR PROTEIN; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; N [3 (4' FLUOROPHENYL) 3 [4' (2 METHYL 3 OXOPYRIDAZIN 5 YLOXY)PHENYL]PROPYL]SARCOSINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; ORG 24461; ORG 24598; PYRIDAZINONE DERIVATIVE; SARCOSINAMIDE; SARCOSINE; SZV 1997; UNCLASSIFIED DRUG;

BINDING SITE; BRAIN LEVEL; COGNITIVE DEFECT; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; MACROGLIA; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; POSITIVE SYNDROME; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TRANSPORT; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SUBSTITUTION REACTION; SYNAPTOSOME;

EID: 84858970423     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.99.2012.1.1     Document Type: Review

References (69)

1. Agoston M, Ronai E, Szabo E, Kiricsi P, Harsing LG., Jr, Szenasi G: 41st Meeting Eur. Brain Behav. Soc. (Abstr.) (2009)
2. Aragon C, Lopez-Corcuera B: Structure, function and regulation of glycine transporters. Eur. J. Pharmacol. 479, 249-262 (2003) (Pubitemid 37377893)
3. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, Tham CS, Tsai C, Jia J, Ashton D, Klitenick MA: ALX5407: A potent and selective inhibitor of the hGlyT1 glycine transporter. Mol. Pharmacol. 60, 1414-1420 (2001) (Pubitemid 33144913)
4. Aubrey KR, Vandenberg RJ: N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy) propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 134, 1429-1436 (2001) (Pubitemid 33131893)
5. Bismuth Y, Kavanaugh MP, Kanner BI: Tyrosine 140 of the gamma-aminobutyric acid transport GAT1 plays a critical role in neurotransmitter recognition. Biol. Chem. 272, 16096-16102 (1997) (Pubitemid 27276422)
6. Bridges TM, Williams R, Lindsley CW: Design of potent GlyT1 inhibitors: In vitro and in vivo profiles. Curr. Opin. Mol. Therap. 10, 591-601 (2008)
7. Brown A, Carlyle I, Clark J, Hamilton W, Gibson S, McGarry G, McEachen S, Rae D, Thorn S, Walker G: Discovery and SAR of Org 24598-A selective glycine uptake inhibitor. Bioorg. Med. Chem. Letters 11, 2007-2009 (2001) (Pubitemid 32709712)
8. Campiani De Angelis M, Armaroli S, Fattorusso C, Catalanotti B, Rammuno A, Nacci V, Novellino E, Grewer C, Ionescu D, Rauen T, Griffiths R, Sinclair C, Fumagalli E, Mennini T: A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3) new glutamate and aspartate analogues as potential neuroprotective agents. J. Med. Chem. 44, 2507-2510 (2001) (Pubitemid 32852140)
9. Caulfield WL, Collie IT, Dickins RS, Epemplu O, McGuire R, Hill DR, McVey G, Morphy JR, Rankovic Z, Sundaram H: The first potent and selective inhibitors of the glycine transporter type 2. J. Med. Chem. 44, 2679-2682 (2001) (Pubitemid 32879707)
10. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M., Heaulme M, Santucci V, Decobert C, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vige X, Biton B, Steinberg R, Farncon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrie P, Scatton B: Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30, 1963-1985 (2005) (Pubitemid 43093498)
11. Drescher KU, Jongen-Relo Al, Behl B, Gross G, Schoemaker H: Comparison of the GlyT1 inhibitor Org-24461 with aripiprazole and risperidone in PCP-induced neurochemical and behavioral changes. Proc. 11th Int. Conf. In Vivo Methods, 456-458 (2006)
12. Durkin JT, Spais CM, Schreiber J, Kopec K, Meyer SL: Amino-terminal isoforms of the human glycine transporter GlyT1 exhibit similar pharmacology. Brain Res. 1374, 1-7 (2011)
13. Eulenburg V, Armsen W, Betz H, Gomeza J: Glycine transporters: Essential regulators of neurotransmission. Trends Biochem. Sci. 30, 325-333 (2005) (Pubitemid 40799051)
14. Gerther U, Andersen PH, Larsson OM, Schousboe A: Neurotransmitter transporters: Molecular function of important drug treatments. Trends Pharm. Sci. 27, 375-383 (2006) (Pubitemid 43977787)
15. Gomeaza J, Ohno K, Betz H: Glycine transporter isoforms in the mammalian central nervous system: Structures, functions and therapeutic promises. Curr. Opin. Drug Discov. Develop. 6, 675-682 (2003) (Pubitemid 37287936)
16. Harsing LG Jr, Solyom S, Salamon C: The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain. Neurochem. Res. 26, 915-923 (2001) (Pubitemid 33021417)
17. Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G: The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study. Pharm. Biochem. Behav. 74, 811-825 (2003) (Pubitemid 36351646)
18. Harsing LG Jr, Gigler G, Moricz K, Agoston M, Marko B, Szabo G, Szenasi G, Juranyi Zs: Antiischemic effects of Org-24461 and NFPS, two glycine transporter type-1 inhibitors. Soc. Neurosci. (Abstr.) 669.16 (2005)
19. Harsing LG Jr, Juranyi Zs, Tapolcsanyi P, Czompa A, Matyus P: Glycine transporter type-1 and its inhibitors. Curr. Med. Chem. 13, 1017-1044 (2006)
20. Harsing LG Jr, Barkoczy J, Szabo G, Matyus P: A new series of sarcosine-containing glycine transporter-1 (GlyT1) inhibitors. Soc. Neurosci. Abstr. 547.6 (2010)
21. Hashimoto K: Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Patents CNS Drug Discover. 1, 43-53 (2006)
22. Hashimoto K: Glycine transporter inhibitors for the treatment of schizophrenia. Open Med. Chem. J. 4, 10-19 (2010)
23. Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ: Pharmacological assessment of the role of glycine transporter GlyT-1 in mediating high affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology 41, 88-96 (2001) (Pubitemid 32607648)
24. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP: Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234-1236 (1994) (Pubitemid 24240973)
25. Javitt D, Frusciante M: Glycyldodecylamide, a phencyclidine behavioural antagonists, blocks cortical glycine uptake: Implication for schizophrenia and substance abuse. Psychopharmacology 129, 96-98 (1997) (Pubitemid 27037457)
26. Javitt DC, Duncan L, Balla A, Serchen H: Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Mol. Psychiatry 10, 276-286 (2005) (Pubitemid 40432681)
27. Johnson JW, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529-531 (1987) (Pubitemid 17056733)
28. Johnson KW, Clemens-Smith A, Nomikos G, Davis R, Phebus L, Shannon H, Love P, Perry K, Katner J, Bymaster F, Yu H, Hoffman BJ: In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors. Ann. NY. Acad. Sci. 1003, 412-414 (2003) (Pubitemid 38083085)
29. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ: The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated reponses in vivo and produces and antipsychotic profile in rodent behavior. J. Neurosci. 23, 7586-7591 (2003) (Pubitemid 37034075)
30. Kopec K, Flood DG, Gasior M, McKanna BAW, Zuvich E, Schreiber J, Salvion JM, Durkin JT, Ator MA, Marino MJ: Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice. Biochem. Pharmacol. 80, 1407-1417 (2010)
31. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL: Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampus-lesioned rats: Reversal by glycine and a glycine transporter inhibitor. Biol. Psychiatry 54, 1162-1170 (2003) (Pubitemid 37464862)
32. Liem-Moolenaar M, Zoethout R, de Boer P, Schmidt M, de Kam M, Cohen A, Franson K, van Gerven J: The effects of a glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J. Psychopharmacol. 24, 1671-1679 (2010)
33. Liem-Moolenaar M, Zoethout R, de Boer P, Schmidt M, de Kam M, Cohen A, Franson K, van Gerven J: The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J. Psychopharmacol. 24, 1681-1687 (2010)
34. Lindsley CW, Zhao Z, Leister WH, O'Brien JA, Lemaire W, Williams DL Jr, Chen T-B, Chang RSL, Burno M, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Rsou NN, Duggan ME, Conn PJ, Hartman GD: Design, synthesis, and in vivo efficacy of novel glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl)-methyl)benzamides. Chem. Med. Chem. 1, 807-811 (2006) (Pubitemid 44384541)
35. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N: Cloning and expression of a spinal cord- and brain-specific glycine transporter with novel structural features. J. Biol. Chem. 268, 22802-22808 (1993) (Pubitemid 23318342)
36. Lowe JA III, Drozda SE, Fisher K, Strick C, Lebel L, Schmidt C, Hiller D, Zandi KS: [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg. Med. Chem. Lett. 13, 1291-1292 (2003) (Pubitemid 36351336)
37. Mallorga PJ, Williams JB, Jacobson M, Marques R, Chaudhary A, Conn PJ, Pettibone DJ, Sur C: Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]- N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy) propyl]sarcosine. Neuropharmacology 45, 585-593 (2003) (Pubitemid 36980815)
38. Manahan-Vaughan D, Wildforster V, Thomsen C: Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur. J. Neurosci. 28, 1342-1350 (2008)
39. Mezler M, Hornberger W, Mueller R, Schmidt M, Amberg W, Braje W, Ochse M, Schoemaker H, Behl B: Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mol. Pharmacol. 74, 1705-1715 (2008)
40. Moyer J: Combination of a glycine transporter (GlyT1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof. WO/2006/066121 A2
41. Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, Barkoczy J, Harsing LG Jr: Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone. Neurochem. Res. 35, 2096-2106 (2010)
42. Nunez E, Martinez-Maza R, Geerlings A, Aragon C, Lopez-Corcuera B: Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)- propyl]sarcosine. Neuropharmacology 49, 922-934 (2005) (Pubitemid 41483898)
43. Oliveras L, Aragon C, Gimenez C, Zafra F: Carboxyl terminus of the glycine transporter GLYT1 is necessary for correct processing of the protein. J. Biol. Chem. 269, 28400-28404 (1994) (Pubitemid 24354584)
44. Oliveras L, Aragon C, Gimenez C, Zafra F: The role of N-glycosylation in the targeting and activity of the GLYT1 glycine transporter. J. Biol. Chem. 270, 9437-9442 (1995)
45. Oliveras L, Aragon C, Gimenez C, Zafra F: Analysis of the transmembrane topology of the glycine transporter GLYT1. J. Biol. Chem. 272, 1211-1217 (1997) (Pubitemid 27034619)
46. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG, Phebus LA, Cauvin AJ, Johnson KW, Jones CK, Hoffmann BJ, Sandusky GE, Walter MW, Porter WJ, Yang L, Merchant KM, Shannon HE, Svensson KA: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55, 743-754 (2008)
47. Pinard E, Alberati D, Borroni E, Fischer H, Hainzl D, Jolidon S, Morcau JL, Marquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg. Med. Chem. Lett. 18, 5134-5139 (2008)
48. Pinard E, Alanine A, Alberati D, Bender M, Borroni E, Bourdeaux P, Brom V, Burner S, Fischer H, Hainzl D, Halm R, Hauser N, Jolidon S, Lengyel J, Marthy HP, Meyer T, Moreau JL, Mory R, Narquizian R, Nettekoven M, Norcross RD, Puellmann B, Schmid P, Schmitt S, Stalder H, Wermuth R, Wettstein JG, Zimmerli D: Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl- 2((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]-methanone (RG 1678), a promising novel medicine to treat schizophrenia. J. Med. Chem. 53, 4603-4614 (2010)
49. Ponce J, Biton B, Benavides J, Avenet P, Aragon C: Transmembrane domain III plays an important role in ion binding and permeation in the glycine transporter GlyT2. J. Biol. Chem. 275, 13856-13862 (2000) (Pubitemid 30257460)
50. Puttfarcken PS, Handen JS, Montgomery DT, Coyle JT, Werling LL: N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices. J. Pharmacol. Exp. Ther. 266, 796-803 (1993) (Pubitemid 23318693)
51. Rowley HL, Martin KF, Marsden CA: Determination of in vivo amino acid neurotransmitters by highperformance liquid chromatography with o-phthaldialdehyde-sulphite derivatisation. J. Neurosci. Methods 57, 93-99 (1995)
52. Singer P, Feldon J, Yee BK: The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation test in C57BL/6 mice. Psychopharmacology 202, 371-384 (2009)
53. Slassi A, Egle I.: Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system disease. Expert. Opin. Ther. Patents 14, 201-214 (2004) (Pubitemid 38240015)
54. Sur C, Kiney GG: The therapeutic potential of glycine transporter-1 inhibitors. Expert. Opin. Ther. Patents 13, 515-521 (2004) (Pubitemid 38714386)
55. Szabo G, Udvari S, Egyed A, Harsing LG Jr: Biochemical characterization of Org 24461 and NFPS in synaptosomal fraction and in cos-7 cells expressing GlyT1 transporters. 20th FEBS Congress (Abstr.) (2004)
56. Szabo G, Szabo E, Egyed A, Harsing LG Jr: In vivo effects of GlyT-1 inhibition on brain receptors and transporter. 25th Eur. Brain Winter Conf. Brain Res. (Abstr.) 96 (2005)
57. Szabo L: Differential effect of GlyT1 inhibitors on the development of ischemic cerebral infarction. J. Cereb. Blood Flow Metabol. 25, S15 (2005)
58. Thomsen C: Glycine transporter inhibitors as novel antipsychotics. Drug Discov. Today Therap. Strat. 3, 539-545 (2006) (Pubitemid 46076172)
59. Thomson CG, Duncan K, Fletcher SR, Huscroft IT, Pillai G, Raubo P, Smith AJ, Stead D: Sarcosine-based indandione hGlyT1 inhibitors. Bioorg. Med. Chem. Lett. 16, 1388-1391 (2006)
60. Torres GE, Gainetdinov RR, Caron MG: Plasma membrane monoamine transporters: Structure, regulation and function. Nat. Rev. Neurosci. 4, 13-25 (2003) (Pubitemid 37271085)
61. Toth E, Weiss B, Banay-Schwartz M, Lajtha A: Effect of glycine derivatives on behavioral changes induced by 3-mercaptoproprionic acid or phencyclidine in mice. Res. Comm. Psychol. Psychiatr. Behav. 11, 1-9 (1986) (Pubitemid 16077647)
62. Tsai G, Lane H-Y, Yang P, Chong M-Y, Lange N: Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55, 452-456 (2004) (Pubitemid 38338531)
63. Vandenberg RJ, Ju P, Aubrey KR, Ryan RM, Mitrovic AD: Allosteric modulation of neurotransmitter transporters at excitatory synapses. Pharm. Sci. 23, 1-11 (2004) (Pubitemid 39489844)
64. Vandenberg RJ: Mutational analysis of glutamate transporters. Handb. Exp. Pharmacol. 175, 113-135 (2006)
65. Vandenberg RJ, Shaddick K, Ju P: Molecular basis for substrate discrimination by glycine transporters. J. Biol. Chem. 282, 14447-14453 (2007) (Pubitemid 47100462)
66. Wolkenberg SE, Sur C: Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. Curr. Topics Med. Chem. 10, 170-186 (2010)
67. Zafra F, Aragon C, Gimenez C: Molecular biology of glycinergic neurotransmission. Mol. Neurobiol. 14, 117-142 (1997) (Pubitemid 127500995)
68. Zafra F, Gimenez C: Glycine transporters and synaptic function. IUBMB Life 60, 810-817 (2008)
69. - dependent neurotransmitter transporters. Nature 473, 215-223 (2005) (Pubitemid 41294479)